Cargando…

A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies

BACKGROUND: Synergistic cytotoxicity with high-dose statins and erlotinib has been demonstrated in preclinical models across a number of tumour types. In this phase I study, we evaluated the safety and potential anti-tumour activity of escalating doses of rosuvastatin in combination with the standar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goss, Glenwood D., Jonker, Derek J., Laurie, Scott A., Weberpals, Johanne I., Oza, Amit M., Spaans, Johanna N., la Porte, Charles, Dimitroulakos, Jim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815068/ https://www.ncbi.nlm.nih.gov/pubmed/27036206 http://dx.doi.org/10.1186/s12967-016-0836-6

Ejemplares similares

Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer
por: Spaans, Johanna N., et al.
Publicado: (2014)

Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies – Past, Present, and Future
por: Spaans, Johanna N., et al.
Publicado: (2014)

Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer
por: Howe, Grant A., et al.
Publicado: (2016)

The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells
por: Weberpals, Johanne I, et al.
Publicado: (2011)

A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
por: Padda, Sukhmani K., et al.
Publicado: (2011)

Effects of rosuvastatin on metabolic profile: Versatility of dose-dependent effect
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2019)

Effects of high rosuvastatin doses on hepatocyte mitochondria of hypercholesterolemic mice
por: Díaz-Zagoya, Juan C., et al.
Publicado: (2021)

A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas
por: Nghiemphu, Phioanh Leia, et al.
Publicado: (2012)

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

Periodic Rosuvastatin or Atorvastatin Dosing Arrays (PRADA): Patient-Centered Practice
por: Christou, Theodore, et al.
Publicado: (2014)

Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis
por: Yang, Han, et al.
Publicado: (2020)

The Effect of Single-Dose Ougan Juice Application on the Pharmacokinetics of Erlotinib
por: Yang, Jin-zhao, et al.
Publicado: (2021)

Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects
por: Kang, Woo Youl, et al.
Publicado: (2018)

Comparison of Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan/Rosuvastatin with Concomitant Administration of Amlodipine/Losartan and Rosuvastatin in Healthy Volunteers
por: Yoon, Deok Yong, et al.
Publicado: (2020)

Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
por: Mita, A C, et al.
Publicado: (2011)

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study
por: Blais, Normand, et al.
Publicado: (2013)

A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium
por: Lheureux, S, et al.
Publicado: (2015)

Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe
por: Yamazaki, Daisuke, et al.
Publicado: (2013)

Effect of fixed‐dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS‐ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe)
por: Kim, Kyung‐Jin, et al.
Publicado: (2016)

Dose-Dependent Effect of Rosuvastatin on VLDL–Apolipoprotein C-III Kinetics in the Metabolic Syndrome
por: Ooi, Esther M.M., et al.
Publicado: (2008)

Comparison of Efficacy and Safety of Fixed Dose Combination of Rosuvastatin and Choline Fenofibrate to Fixed Dose Combination of Rosuvastatin and Fenofibrate in Patients of Mixed Dyslipidemia: A Randomized, Open-label, Multicentre Clinical Trial in Indian Population
por: Barkate, Hanmant, et al.
Publicado: (2018)

Effect of High Dose Rosuvastatin Loading before Percutaneous Coronary Intervention on Contrast-Induced Nephropathy
por: Yun, Kyeong Ho, et al.
Publicado: (2014)

Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians
por: Lee, Jieon, et al.
Publicado: (2018)

An Expert Opinion on the Role of the Rosuvastatin/Amlodipine Single Pill Fixed Dose Combination in Cardiovascular Prevention
por: Gallo, Giovanna, et al.
Publicado: (2023)

Comparative Study of Low Doses of Rosuvastatin and Atorvastatin on Lipid and Glycemic Control in Patients with Metabolic Syndrome and Hypercholesterolemia
por: Park, Jong-Seon, et al.
Publicado: (2010)

Effects of High-Dose Rosuvastatin on Ventricular Remodelling and Cardiac Function in ST-Segment Elevation Myocardial Infarction
por: Luo, Rong, et al.
Publicado: (2020)

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial
por: Goss, Glenwood D, et al.
Publicado: (2021)

Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients
por: Liu, Lin L., et al.
Publicado: (2015)

Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer
por: Schöttle, Jakob, et al.
Publicado: (2015)

Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity
por: Yamanaka, Yumie, et al.
Publicado: (2017)

Histologic and Genotypic Characterization of Lung Cancer in the Inuit Population of the Eastern Canadian Arctic
por: Goss, Glenwood D., et al.
Publicado: (2022)

Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)
por: Clearfield, Michael B, et al.
Publicado: (2006)

Continuing Exposure to Low-Dose Nonylphenol Aggravates Adenine-Induced Chronic Renal Dysfunction and Role of Rosuvastatin Therapy
por: Yen, Chia-Hung, et al.
Publicado: (2012)

Comparison of the incidence of contrast-induced nephropathy after primary PCI in patients receiving high-dose rosuvastatin and atorvastatin
por: Golshani, Samad, et al.
Publicado: (2022)

582. Safety and Efficacy of High-Dose Ganciclovir versus Standard Dosing for Cytomegalovirus Viremia in Solid Organ Transplant (SOT) Recipients
por: Fitzmaurice, Mary Grace, et al.
Publicado: (2020)

Comparison of Radiomic Models Based on Low-Dose and Standard-Dose CT for Prediction of Adenocarcinomas and Benign Lesions in Solid Pulmonary Nodules
por: Liu, Jieke, et al.
Publicado: (2021)

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
por: Van Cutsem, E, et al.
Publicado: (2014)

Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer
por: PETTY, W. JEFFREY, et al.
Publicado: (2013)

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
por: Subbiah, Vivek, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2edbt3a0e6b49uj1s3kom6s25h